Needham Maintains Buy on Immuneering, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 80.2%

Neg 0% Neu 0% Pos 80.2%

Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.

Comments

No comments yet. Be the first!